ArticleNature nanotechnology2022
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles.
Article in Nature nanotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 122 citations in OpenAlex.
- From RNA design to delivery: Computational strategies for functional RNA therapeutics.Bioactive materials · 2027Review
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Mechanisms and determinants of mRNALipid Nanoparticle biodistribution: From pharmacokinetics to clinical translation.Bioengineering & translational medicine · 2026Review
- Structural evolution of ionizable lipids for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Current Advances in Liver-Targeted Drug Delivery: Synthetic, Biological, and Biomimetic Platforms.International journal of molecular sciences · 2026Review
- Nanoparticles for Drug Delivery: Design, Mechanisms, and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Non-invasive nanoparticle barcoding in nonhuman primates.Nature biotechnology · 2026Article
- Towards clinical translation of nanomedicines: Formulation scale-up and model systems.Advanced drug delivery reviews · 2026Review
- Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives.MedComm · 2026Review
- Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded Antibodies.Molecular pharmaceutics · 2026Article
- Lipid nanoparticle screening in nonhuman primates with minimal loss of life.Nature biotechnology · 2026Article
- Lipid nanoparticles for bone marrow-targeted RNA therapeutics.Journal of nanobiotechnology · 2026Review
- Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.Communications medicine · 2026Review
- Controlling In Vitro mRNA Polyadenylation by Monitoring Poly(A) Polymerase Consumption of ATP.International journal of molecular sciences · 2026Article
- A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors.Nature biotechnology · 2026Article
- Optimizing C14120-based LNPs forMolecular therapy. Nucleic acids · 2026Article
- High-Throughput In Vivo Screening Using Barcoded mRNA Identifies Lipid Nanoparticles With Extrahepatic Tropism for In Situ Immunoengineering.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.bioRxiv : the preprint server for biology · 2026Article
- Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma.Nature communications · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticles are tested in mice and non-human primates before being selected for clinical trials. Yet the extent to which mRNA delivery, as well as the cellular response to mRNA drug delivery vehicles, is conserved across species in vivo is unknown. Using a species-independent DNA barcoding system, we have compared how 89 lipid nanoparticles deliver mRNA in mice with humanized livers, primatized livers and four controls: mice with 'murinized' livers as well as wild-type BL/6, Balb/C and NZB/BlNJ mice. We assessed whether functional delivery results in murine, non-human primate and human hepatocytes can be used to predict delivery in the other species in vivo. By analysing in vivo hepatocytes by RNA sequencing, we identified species-dependent responses to lipid nanoparticles, including mRNA translation and endocytosis. These data support an evidence-based approach to making small-animal preclinical nanoparticle studies more predictive, thereby accelerating the development of RNA therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.